Gene Therapy Trial for Mitochondrial Disease of Retina Found Safe, Can Continue
An independent Data Safety Monitoring Board (DSMB) has found GS030, GenSight Biologics’ candidate gene therapy for retinitis pigmentosa, safe and recommended the company’s PIONEER trial continue as planned. PIONEER (NCT03326336) is a Phase 1/2 trial currently investigating the safety and tolerability of increasing doses of GS030…